glp 1 news today glp-1 obesity drug updates New research is challenging long-held assumptions about GLP-1 Prescriptions Quadruple Since 2021

Description

In a study with 39 participants (BMI 30 kg/m 2 ), GLP-1RAs such as semaglutide and liraglutide, combined with standard weight management, led to significant weight loss and fewer headache days compared to controls, with lower acetazolamide doses [92]

Positive chronotropic and inotropic effects in heart failure have been demonstrated with infusions of GLP-1 in animal studies and small short-term studies of patients with acute heart failure post-myocardial infarction and in patients with chronic systolic and diastolic dysfunction.12 Tirzepatide has demonstrated additional benefits of slowing renal decline when used in conjunction with insulin and reduced all-cause mortality compared with other GLP-1RAs.13 In patients with type 2 diabetes mellitus (T2DM), reductions in composite renal outcomes and renal failure have been outlined in meta-analyses.14 Of great interest for gastroenterologists and hepatologists is the potential for using GLP-1 agonists in metabolic dysfunction-associated steatotic liver disease (MASLD)